Journal of Volgograd State Medical University · Oct 15, 2026
Use of ortho-vanillin as a senolytic agent in degeneration of intervertebral discs
By Berezhnaya ES, Savustyanenko AV, Morozov NM et al.
Today, along with other factors, significant emphasis is placed on stress-induced cellular senescence – the emergence of prematurely aged cells–in the pathogenesis of degeneration. Agents that reduce the number of senescent cells are referred to as senolytics. The aim of the study was to summarize the results of studies on the use of the new senolytic ortho-vanillin to combat degenerative changes in intervertebral discs. Research methodology: The present work was conducted as a narrative review. A literature search was performed across eLIBRARY.ru, PubMed, Science Direct, Google Scholar, and SciELO databases using the keywords: ortho-vanillin and senolytic. A total of 6 experimental studies published between 2019 and 2025 were identified. The results of the research: When analyzing literary sources, compelling evidence has been found regarding the therapeutic potential of ortho-vanillin. Research indicates that this compound effectively reduces senescent cell populations. This process occurs through both the classical induction of apoptosis (programmed cell death) and several alternative biological mechanisms independent of the apoptotic cascade. In addition to eliminating damaged cells, ortho-vanillin significantly impacts the tissue microenvironment by markedly reducing the senescence-associated secretory phenotype (SASP). This minimizes the negative impact of inflammatory factors on neighboring healthy cells. A crucial aspect of the compound’s action is its ability to stimulate regenerative processes; specifically, a significant increase in the biosynthesis of extracellular matrix components, notably proteoglycans, has been recorded. These therapeutic effects have been validated across various experimental models. Positive outcomes were observed in both isolated in vitro cell cultures derived from degenerated human intervertebral disc tissues and more complex ex vivo whole-disc cultures affected by degeneration. Conclusion: The pilot experimental studies presented have convincingly demonstrated the potential significance of ortho-vanillin as a senolytic for disease-modifying therapy in patients with intervertebral disc degeneration and low back pain. Further experimental and clinical investigations of this agent are required.
doi.org/10.19163/1994-9480-2026-23-3-66-73Open accessInterventions